Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $178,295 | $218,588 | $227,564 | $198,480 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Cost of Goods Sold | $45,640 | $58,214 | $52,430 | $50,549 |
| Gross Profit | $132,655 | $160,374 | $175,134 | $147,931 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| R&D Expenses | $31,901 | $35,478 | $55,808 | $30,863 |
| G&A Expenses | $18,434 | $23,023 | $22,865 | $28,452 |
| SG&A Expenses | $94,238 | $96,733 | $103,848 | $95,926 |
| Sales & Mktg Exp. | $75,804 | $73,710 | $80,983 | $67,474 |
| Other Operating Expenses | -$567 | $1,597 | $16 | $670 |
| Operating Expenses | $125,572 | $133,808 | $159,672 | $127,459 |
| Operating Income | $7,083 | $26,566 | $15,462 | $20,472 |
| % Margin | 4% | 12.2% | 6.8% | 10.3% |
| Other Income/Exp. Net | $0 | -$40,617 | $34,154 | $67,207 |
| Pre-Tax Income | -$3,344 | -$14,051 | $49,616 | $87,679 |
| Tax Expense | $4,917 | $1,652 | $13,229 | $1,862 |
| Net Income | $1,573 | -$12,399 | $36,387 | $85,817 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| Weighted Avg Shares Out | 125,999 | 125,998 | 126,248 | 125,998 |
| Weighted Avg Shares Out Dil | 126,220 | 126,600 | 126,600 | 126,743 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $67,207 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8,937 | $11,301 | $11,553 | $0 |
| EBITDA | $16,020 | $37,867 | $28,068 | $20,472 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |